Logo image of EXAS

EXACT SCIENCES CORP (EXAS) Stock Fundamental Analysis

NASDAQ:EXAS - Nasdaq - US30063P1057 - Common Stock - Currency: USD

53.36  -0.5 (-0.93%)

After market: 53.36 0 (0%)

Fundamental Rating

4

Overall EXAS gets a fundamental rating of 4 out of 10. We evaluated EXAS against 555 industry peers in the Biotechnology industry. The financial health of EXAS is average, but there are quite some concerns on its profitability. EXAS has a correct valuation and a medium growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year EXAS has reported negative net income.
EXAS had a positive operating cash flow in the past year.
In the past 5 years EXAS always reported negative net income.
In multiple years EXAS reported negative operating cash flow during the last 5 years.
EXAS Yearly Net Income VS EBIT VS OCF VS FCFEXAS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M -400M -600M -800M -1B

1.2 Ratios

EXAS has a Return On Assets of -17.86%. This is in the better half of the industry: EXAS outperforms 78.74% of its industry peers.
With a decent Return On Equity value of -42.55%, EXAS is doing good in the industry, outperforming 68.83% of the companies in the same industry.
Industry RankSector Rank
ROA -17.86%
ROE -42.55%
ROIC N/A
ROA(3y)-10.17%
ROA(5y)-11.23%
ROE(3y)-23.27%
ROE(5y)-24.85%
ROIC(3y)N/A
ROIC(5y)N/A
EXAS Yearly ROA, ROE, ROICEXAS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10 -20 -30 -40

1.3 Margins

The Gross Margin of EXAS (69.02%) is better than 81.62% of its industry peers.
EXAS's Gross Margin has declined in the last couple of years.
EXAS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 69.02%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.06%
GM growth 5Y-1.57%
EXAS Yearly Profit, Operating, Gross MarginsEXAS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300 -400

More info and screens

4

2. Health

2.1 Basic Checks

EXAS does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, EXAS has more shares outstanding
Compared to 5 years ago, EXAS has more shares outstanding
Compared to 1 year ago, EXAS has a worse debt to assets ratio.
EXAS Yearly Shares OutstandingEXAS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
EXAS Yearly Total Debt VS Total AssetsEXAS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B

2.2 Solvency

Based on the Altman-Z score of 1.29, we must say that EXAS is in the distress zone and has some risk of bankruptcy.
EXAS has a Altman-Z score of 1.29. This is in the better half of the industry: EXAS outperforms 67.21% of its industry peers.
EXAS has a debt to FCF ratio of 15.69. This is a negative value and a sign of low solvency as EXAS would need 15.69 years to pay back of all of its debts.
The Debt to FCF ratio of EXAS (15.69) is better than 91.53% of its industry peers.
A Debt/Equity ratio of 0.97 indicates that EXAS is somewhat dependend on debt financing.
The Debt to Equity ratio of EXAS (0.97) is worse than 76.58% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.97
Debt/FCF 15.69
Altman-Z 1.29
ROIC/WACCN/A
WACC7.34%
EXAS Yearly LT Debt VS Equity VS FCFEXAS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1B 2B 3B

2.3 Liquidity

A Current Ratio of 2.73 indicates that EXAS has no problem at all paying its short term obligations.
EXAS has a worse Current ratio (2.73) than 67.57% of its industry peers.
EXAS has a Quick Ratio of 2.38. This indicates that EXAS is financially healthy and has no problem in meeting its short term obligations.
EXAS has a Quick ratio of 2.38. This is in the lower half of the industry: EXAS underperforms 69.01% of its industry peers.
Industry RankSector Rank
Current Ratio 2.73
Quick Ratio 2.38
EXAS Yearly Current Assets VS Current LiabilitesEXAS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

More info and screens

6

3. Growth

3.1 Past

EXAS shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -317.42%.
The Revenue has grown by 11.57% in the past year. This is quite good.
Measured over the past years, EXAS shows a very strong growth in Revenue. The Revenue has been growing by 25.78% on average per year.
EPS 1Y (TTM)-317.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%10%
Revenue 1Y (TTM)11.57%
Revenue growth 3Y16.01%
Revenue growth 5Y25.78%
Sales Q2Q%10.86%

3.2 Future

Based on estimates for the next years, EXAS will show a very strong growth in Earnings Per Share. The EPS will grow by 22.14% on average per year.
EXAS is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 10.21% yearly.
EPS Next Y86.82%
EPS Next 2Y43.12%
EPS Next 3Y29.79%
EPS Next 5Y22.14%
Revenue Next Year12.81%
Revenue Next 2Y12.78%
Revenue Next 3Y12.48%
Revenue Next 5Y10.21%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
EXAS Yearly Revenue VS EstimatesEXAS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 1B 2B 3B 4B 5B
EXAS Yearly EPS VS EstimatesEXAS Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 2 -2 4 -4 6

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for EXAS. In the last year negative earnings were reported.
With a Price/Forward Earnings ratio of 197.66, EXAS can be considered very expensive at the moment.
EXAS's Price/Forward Earnings ratio is rather cheap when compared to the industry. EXAS is cheaper than 87.57% of the companies in the same industry.
EXAS's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 21.90.
Industry RankSector Rank
PE N/A
Fwd PE 197.66
EXAS Price Earnings VS Forward Price EarningsEXAS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 100 150

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, EXAS is valued cheaper than 90.99% of the companies in the same industry.
EXAS's Price/Free Cash Flow ratio is rather cheap when compared to the industry. EXAS is cheaper than 92.07% of the companies in the same industry.
Industry RankSector Rank
P/FCF 67.49
EV/EBITDA 233.83
EXAS Per share dataEXAS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
A more expensive valuation may be justified as EXAS's earnings are expected to grow with 29.79% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y43.12%
EPS Next 3Y29.79%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for EXAS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

EXACT SCIENCES CORP

NASDAQ:EXAS (7/3/2025, 7:20:54 PM)

After market: 53.36 0 (0%)

53.36

-0.5 (-0.93%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-01 2025-05-01/amc
Earnings (Next)07-29 2025-07-29/amc
Inst Owners98.12%
Inst Owner Change-1.1%
Ins Owners0.84%
Ins Owner Change5.81%
Market Cap10.07B
Analysts85.29
Price Target70.72 (32.53%)
Short Float %4.26%
Short Ratio2.59
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-715.5%
Min EPS beat(2)-1391.93%
Max EPS beat(2)-39.07%
EPS beat(4)2
Avg EPS beat(4)-339.36%
Min EPS beat(4)-1391.93%
Max EPS beat(4)72.6%
EPS beat(8)5
Avg EPS beat(8)-153.52%
EPS beat(12)9
Avg EPS beat(12)-93.28%
EPS beat(16)10
Avg EPS beat(16)-73.52%
Revenue beat(2)1
Avg Revenue beat(2)0.18%
Min Revenue beat(2)-0.27%
Max Revenue beat(2)0.62%
Revenue beat(4)1
Avg Revenue beat(4)-0.87%
Min Revenue beat(4)-3.19%
Max Revenue beat(4)0.62%
Revenue beat(8)2
Avg Revenue beat(8)-0.38%
Revenue beat(12)6
Avg Revenue beat(12)1.08%
Revenue beat(16)10
Avg Revenue beat(16)1.57%
PT rev (1m)0.06%
PT rev (3m)-0.85%
EPS NQ rev (1m)-11.98%
EPS NQ rev (3m)-52.46%
EPS NY rev (1m)-29.99%
EPS NY rev (3m)-75.61%
Revenue NQ rev (1m)-0.01%
Revenue NQ rev (3m)2.44%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.38%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 197.66
P/S 3.56
P/FCF 67.49
P/OCF 31.1
P/B 4.2
P/tB N/A
EV/EBITDA 233.83
EPS(TTM)-5.51
EYN/A
EPS(NY)0.27
Fwd EY0.51%
FCF(TTM)0.79
FCFY1.48%
OCF(TTM)1.72
OCFY3.22%
SpS14.99
BVpS12.71
TBVpS-5.08
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -17.86%
ROE -42.55%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 69.02%
FCFM 5.27%
ROA(3y)-10.17%
ROA(5y)-11.23%
ROE(3y)-23.27%
ROE(5y)-24.85%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.06%
GM growth 5Y-1.57%
F-Score4
Asset Turnover0.5
Health
Industry RankSector Rank
Debt/Equity 0.97
Debt/FCF 15.69
Debt/EBITDA 48.39
Cap/Depr 81.18%
Cap/Sales 6.17%
Interest Coverage N/A
Cash Conversion 671.19%
Profit Quality N/A
Current Ratio 2.73
Quick Ratio 2.38
Altman-Z 1.29
F-Score4
WACC7.34%
ROIC/WACCN/A
Cap/Depr(3y)84.38%
Cap/Depr(5y)130.41%
Cap/Sales(3y)7.28%
Cap/Sales(5y)12.95%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-317.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%10%
EPS Next Y86.82%
EPS Next 2Y43.12%
EPS Next 3Y29.79%
EPS Next 5Y22.14%
Revenue 1Y (TTM)11.57%
Revenue growth 3Y16.01%
Revenue growth 5Y25.78%
Sales Q2Q%10.86%
Revenue Next Year12.81%
Revenue Next 2Y12.78%
Revenue Next 3Y12.48%
Revenue Next 5Y10.21%
EBIT growth 1Y30.4%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year320.62%
EBIT Next 3Y82.5%
EBIT Next 5Y50.87%
FCF growth 1Y150%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y467.79%
OCF growth 3YN/A
OCF growth 5YN/A